Transcript Highlights:

• So right now, it's not restricted to just personnel or contracts.
• There are, though, no fines authorized against pharmacies.
• For those pharmacies, the board is directed to work collaboratively with any noncompliant pharmacy through
• I am the chair of the New Mexico Pharmacy Business Council, representing all independent pharmacies across
• I can imagine if the pharmacies, 30 of pharmacies in New Mexico, stop piling other necessity medications

Keywords: 996, all

Transcript Highlights:

• Thus streamlining the process for pharmacy appeals.
• It prohibits using a formulary to ban the use of certain pharmacies by an enrollee.
• It prohibits using formulary to ban the use of certain pharmacies by an enrollee.
• , and those contracts And those contracts are conducted between fairly sophisticated operators.
• Apeic effective rate pricing: pharmacies can't predict reimbursement.

Summary: The House Insurance Committee met on April 29 with a quorum present and took up several insurance and health care-related bills. SB 192, a dental reimbursement bill, was amended to allow dentists to opt in electronically to credit-card payment methods and to clarify applicability and effective date; it was reported as amended. SB 84 would require prostate cancer screening coverage for men over 40 under current clinical guidelines and prohibit cost-sharing; supporters from the American Cancer Society said Louisiana has a high incidence of prostate cancer and that out-of-pocket costs deter early screening. The committee adopted amendments and reported the bill as amended. SB 275, dealing with reimbursement and network participation for certified registered nurse anesthetists, drew support from nursing and hospital groups and was reported favorably. SB 169, a cleanup bill on biomarker testing, was also amended and reported. The committee spent substantial time on SB 401, which creates a temporary prescription drug affordability board to review pricing data on selected drugs and report findings to the legislature. Supporters said the board would improve transparency and help lawmakers understand drug pricing trends; opponents raised concerns about confidentiality, market effects, and the lack of a defined policy outcome beyond reporting. Amendments narrowed the scope, added confidentiality protections, and removed opposition cards, and the bill was reported as amended. SB 387, a major PBM reform bill tied to SB 401, would change PBM compensation, rebate handling, formulary practices, audits, and appeals, while excluding ERISA plans after discussion and amendment. Supporters argued it would curb spread pricing and other practices that raise costs, while opponents from the Pelican Institute and PCMA warned it would interfere with private contracts, reduce flexibility, and could raise premiums or disrupt city, school board, and small-group plans. After extensive debate and a roll call, SB 387 was reported with amendments by a 10-4 vote. The committee also considered SB 241, which requires certain insurance adjusters and public adjusters to include license numbers in written communications. After amendments limiting the requirement to individual licenses and removing one statutory reference, the bill was reported as amended. Throughout the meeting, members and witnesses repeatedly discussed the need for transparency in drug pricing and PBM practices, the role of ERISA and non-ERISA plans, and potential impacts on public employers and consumers.

Transcript Highlights:

• “To answer what this is: our pharmacy benefit consultant.
• I want to make sure how much is this contract for?”
• underlying contract, is that correct?”
• So if the written contract has the one point of...
• Next item is the review of the CompSack contract.

Keywords: 1204, all

Summary: The State Insurance Programs Oversight Subcommittee met on June 17 and reviewed a series of Employee Benefits Division and Office of Property Risk items. Grant Wallace presented March and April formulary changes, including moving to lower-cost generic and preferred drugs, leaving several new-to-market drugs not covered, and adjusting migraine and diabetes medications; the committee approved those recommendations. The subcommittee also approved a cell and gene therapy policy that excludes automatic coverage for those therapies so they can undergo prior authorization and review, with members emphasizing that the policy was intended to create review, not an absolute denial, and that expedited appeals would remain available. Members spent significant time discussing the UAMS pharmacy benefit consultant amendment. Wallace explained that the contract included both basic services and optional services related to coupon and rebate management and prior authorization support, but the written materials created confusion over the dollar amount. After questions about whether the committee was approving a higher amount than the base contract and whether the optional services duplicated work already being done by Navitus, the committee agreed to review the item with a contingency that any use of the optional services would return to the committee for approval. The committee also reviewed and approved the U.S. Able Mutual/Blue Advantage third-party administrator contract, the CompSack employee assistance program contract, and the proposed 2027 employee and public employee rates, which call for a 9.8% increase for state employees and a 4.9% increase for public school employees. On the property risk side, the committee reviewed permanent rules for the property insurance program, a contingency-fee subrogation contract with Denenberg-Tuffley, and renewals for Sedgwick claims management, Actuarial Advantage, and Stevens Capital Management. Wallace said Sedgwick had faced delays after a major winter storm and other weather events, but performance guarantees and communication expectations were being added; members discussed whether a shorter renewal term would be preferable, but the item was reviewed. The committee also approved the 2026-27 captive insurance program rates, which Wallace said would lower the overall rate by 10% while keeping minimum deductibles unchanged. He noted the program had stabilized after a difficult first year and that the rate structure was now based on a more transparent actuarial foundation. The meeting ended with an update that the UnitedHealthcare rebid was nearing completion and would return in August, and the committee adjourned after approving the remaining items.

Transcript Highlights:

• have a contract with American Associated<01:40:45.040> Pharmacies,<01:40:45.760> which
• Um, so when it says contracts between a pharmacy services administrative organization and a pharmacy
• entity. says contracts between a pharmacy says contracts between a pharmacy services<02:02:51.840>
• Um, to provide administrative services to pharmacies and enter contracts with pharmacies and enter contracts
• with pharmacies and enter contracts with pharmacies and enter contracts with third<02:04:46.239><

Keywords: 928, house, all

Summary: The committee first heard Senate Bill 47, sponsored by Sen. Regina Birdsell at the request of the Insurance Department. The bill would codify the department’s interpretation that a birth mother’s health insurance is the primary coverage for a newborn, unless the mother has no insurance or coverage under an employer-sponsored plan. Birdsell and Insurance Commissioner DJ Benton Court said the measure is a clarification of existing practice and intended to protect vulnerable newborns; a question from Rep. Miles clarified that if a young woman is on her parents’ policy, the newborn would generally be covered under that family coverage. The hearing on SB 47 was then closed. The committee then took up Senate Bill 121, introduced by Grant Bosi for Sen. Kevin Avard, which would require insurers to notify the Insurance Department when they stop writing an entire line of business or, in some cases, Medicare Advantage plans. Commissioner Benton Court said the bill arose from disruption in the Medicare Advantage market, where consumers, brokers, and the department were confused by carriers changing or ending offerings; he said the department wanted a simple notification requirement so it could better advise consumers. Members discussed network adequacy, county-based service areas, and the fact that the bill would make notice a condition of licensure, with possible fines or license action for noncompliance. Witness Paula Rogers of AHIP said her group supported the bill if amended, and the department indicated it would support a change from a 120-day notice period to 90 days to align with state rules; the committee planned to work on an amendment in subcommittee. Finally, the committee heard Senate Bill 247, introduced by Rep. Brian Cole, which would prohibit network exclusion of pharmacies that refuse to dispense prescriptions when PBM reimbursement is below acquisition cost. Cole argued the bill is meant to stop pharmacies from being forced to sell drugs at a loss, describing PBMs as middlemen and saying the measure is a compromise that protects local pharmacies. Members questioned whether consumers would pay more and whether pharmacies voluntarily enter PBM contracts; Cole responded that the bill would let pharmacies refuse unprofitable fills while consumers could still obtain the drug through mail order or other channels. He also said the issue has changed over time because the practice now affects a much larger share of generics and is concentrated among a few PBMs. The hearing remained open as questions continued, with no vote taken in the excerpt.

Transcript Highlights:

• I now have a contract with American Associated Pharmacies, which is my buying group.
• have a contract with American Associated<01:40:45.040> Pharmacies,<01:40:45.760> which
• But, okay, if a pharmacy signs a contract and agrees to a price, shouldn't that be able to change if
• So when it says contracts between a pharmacy services administrative organization and a pharmacy shall
• “To provide administrative services to pharmacies and enter contracts with third-party payers.

Keywords: 928, house, all

Summary: The committee first heard Senate Bill 47, sponsored by Senator Regina Birdsell at the request of the Insurance Department. The bill would clarify that a birth mother’s health insurance is the primary policy for a newborn’s care unless the mother has no coverage or no employer-sponsored coverage. Birdsell and Insurance Commissioner DJ Benton Court said the measure simply codifies the department’s long-standing interpretation of existing law. Representative Miles asked whether the coverage would extend to a grandchild if a young woman on her parents’ plan had a baby, and Birdsell said it would. The hearing on SB 47 was then closed. The committee next heard Senate Bill 121, introduced by Grant Bosi for Senator Kevin Avard. The bill requires insurers to notify the Insurance Department when they stop writing an entire line of business or, in some cases, when they change Medicare Advantage offerings. Benton Court said the bill was prompted by disruption in the Medicare Advantage market, where consumers and the department were confused by carriers exiting, changing plans, or narrowing offerings. He said the department does not regulate Medicare Advantage itself, but does license the carriers, and the notice requirement would help the department advise consumers; he also said noncompliance could affect a carrier’s license and could lead to fines. Members discussed the notice period, and the department and AHIP indicated support for changing it from 120 days to 90 days to align with federal timing. The hearing was closed with plans to work on an amendment in subcommittee. Finally, the committee heard Senate Bill 247, introduced by Representative Brian Cole, which would prohibit network exclusion for pharmacies that refuse to dispense prescriptions when PBM reimbursement is below acquisition cost. Cole said the bill is meant to stop pharmacies from being forced to sell at a loss. Members questioned whether pharmacies voluntarily enter PBM contracts, whether the bill would raise consumer prices, and whether it would mainly affect independent pharmacies. Cole and others said the issue has changed over time because PBMs now control a much larger share of the market, and that the bill would let pharmacies refuse loss-making fills and direct patients to mail order instead. The discussion also noted that the bill excludes Medicare and Medicaid and that the current proposal does not create a middle-ground option for patients to pay a premium at the counter.

Bills: HB62, HB124, HB182, HB193, HB198, HB203, HB223, HB237, HB469, HB486, HB574, HB779, HB796, HB919, SCR2, SB4, SB36, SB38, SB109, SB152, SB168, SB195, SB216, SB221, SB236, SB404

Keywords: Louisiana Women's Policy, gender equality, policy research, commission membership, women's representation, Domestic Violence, judicial experience, legislation, criminal law, family law, HB182, sexual assault, rape kit, forensic examination, forensic medical exam, sexual assault survivor, sexual assault nurse examiner, SANE, emergency department, hospital staffing

Transcript Highlights:

• Next, we'll take up tab 6, Senate Bill 1256 on pharmacy audits by Senator Graal.
• , and fairly across all types of pharmacies.
• independent pharmacies, PBM-owned pharmacies, and PBM-affiliated pharmacies.
• integrity of the pharmacy system, but without destroying pharmacy practices over simple clerical errors
• from making those contracts and those arrangements?

Bills: S0326, S0598, S0632, S0786, S1110, S1256, S1380, S1588, S7042, S7044

Keywords: curators, estates, court appointment, fiduciary duty, bond requirements, removal, surrogate, funeral homes, cemetery law, cremation, embalmer, funeral director, preneed contract, preneed funeral, human remains, unclaimed cremated remains, disposition of remains, hospice, palliative care, end-of-life care

Summary: The Banking and Insurance Committee met with a quorum present and temporarily postponed SB 7042 on legal tender and SB 1380 before taking up the remaining agenda. The committee first reported favorably C.S. for SB 326, which modernizes Florida’s curator statute in probate law by clarifying when curators may be appointed, what they may do, and what oversight applies. It then reported favorably SB 1256, which standardizes PBM pharmacy audits by requiring uniform audit standards, scope, frequency, penalties, and due process protections for pharmacies; testimony from pharmacists emphasized concerns about conflicts of interest, excessive audits, and disproportionate penalties, while preserving fraud investigations. The committee also reported favorably C.S. for SB 598 on funeral and cemetery services after adopting an amendment that removed provisions on civil damages caps and phasing out direct disposers; the bill updates licensure and contract rules and addresses unclaimed remains. SB 632, which sets insurance requirements for transportation network companies during the period after a ride is accepted but before pickup, was reported favorably despite opposition from an attorney who argued the existing coverage framework should not be reduced. C.S. for SB 786, creating a nonjudicial process to close out undisputed trusts and discharge trustees, was also reported favorably. The committee then took up SB 1110, a major bill expanding Medicaid and private insurance coverage for medically necessary orthotics and prosthetics, including activity limbs, and requiring annual reporting. After adopting an amendment clarifying eligible recipients, the committee heard extensive emotional testimony from amputees, parents, and advocates describing the medical, developmental, and financial importance of prosthetic coverage, and members spoke in strong support before the bill was reported favorably. Later, the committee considered SB 1588, which implements last session’s legal tender law by refining definitions, narrowing custodian provisions, eliminating unnecessary examination requirements, and repealing the sunset clause; members raised questions about verification and anti-money-laundering concerns, but the bill was reported favorably. Finally, the committee approved SPB 7044 as a committee bill to expand public records exemptions to records relating to newly regulated custodians of gold and silver. The meeting concluded with senators recording additional affirmative votes on selected bills and adjourning.

Transcript Highlights:

• , 1,600 pharmacies...
• , 1600 PHARMACIES  370 Closed last year.
• Chair McClure: Eric Larson, Florida Pharmacy Association, is here for information.
• My name is Eric Larson, also an independent pharmacy owner in Central Florida.
• A small town has one pharmacy, and you have an hour drive to the next one?

Summary: The committee first took up CS/House Bill 981, which would restore the Ocklawaha River and related natural resources. Supporters, including environmental groups, Save the Manatee Club, business owners, and Reunite the Rivers advocates, argued the bill would improve manatee habitat, fish passage, flood protection, tourism, and long-term economic returns while reducing dam maintenance costs. Opponents and skeptics focused on concerns about water quality, nutrient loading in the St. Johns River, loss of the Rodman Reservoir’s habitat and water-supply value, and potential ecological and economic harms. Members in debate largely supported the restoration effort, and the bill was reported favorably on a unanimous vote. The committee then heard HB 697, the PRICE Act, which would use international reference pricing to set a drug cost benchmark, address pharmacy benefit manager practices, and require health plans to keep drug prices stable for the year. The sponsor said the bill would lower costs and improve access, especially for uninsured Floridians. Supporters, including independent pharmacists, argued PBMs are squeezing pharmacies and that the bill could help lower prices. Opponents from BioFlorida and PhRMA warned the proposal could disrupt the national drug supply chain, fail to pass savings to patients, and lead to shortages, reduced access, and less innovation. After debate, the bill passed favorably, with Rep. Chambliss voting no. The committee also considered CS/HB 1081, which was amended to include private colleges and universities with NCA designation in the program. After brief discussion and support from United Way Miami, the committee reported the bill favorably. Finally, CS/HB 177 was introduced as a framework for Florida’s regional councils to cross-assign bills among regions; it received supportive testimony and was also reported favorably. The meeting then adjourned.

Transcript Highlights:

• , and fairly across all types of pharmacies.
• independent pharmacies, PBM-owned pharmacies, and PBM-affiliated pharmacies.
• integrity of the pharmacy system, but without destroying...
• Fair audits protect the integrity of the pharmacy system, but without destroying pharmacy practices over
• Like if I'm a funeral director and I have a contract with some entities...

Summary: The Banking and Insurance Committee took up several bills, beginning with CS/SB 326, which modernizes Florida’s curator statute in probate law by clarifying when curators may be appointed, what they may do, and the oversight required. The bill was reported favorably without opposition. The committee then heard SB 1256 on pharmacy audits, which would require PBM audits of pharmacies to follow uniform standards and provide due process protections; pharmacists testified in support, describing current audits as burdensome and conflicted. That bill was also reported favorably. Members next considered CS/SB 598 on funeral, cemetery, and consumer services. An amendment was adopted removing provisions on civil damage caps and phasing out direct disposers, and the bill was then reported favorably. SB 632, dealing with transportation network company insurance, would set coverage requirements for the period after a ride is accepted but before pickup; an opponent argued the existing insurance framework should not be reduced, but the bill passed on a divided vote and was reported favorably. CS/SB 786 on trusts, creating a nonjudicial process to close uncontested trusts and discharge trustees, was supported by banking and legal groups and reported favorably. The committee then took up CS/SB 1110 on Medicaid, health insurance, and HMO coverage for orthotics and prosthetics. A delete-all amendment clarified eligible recipients, and the bill drew extensive emotional testimony from amputees, parents, and advocates describing the high cost of activity limbs and the benefits for children’s health and participation. Several senators praised the testimony and the policy, and the bill was reported favorably. Finally, SB 1588 on legal tender refined last session’s gold-and-silver law, and SPB 7044 created related public-records exemptions for custodians of gold and silver; both were reported favorably, with SPB 7044 adopted as a committee bill. The meeting ended with senators recording additional affirmative votes on selected bills and adjournment.

Transcript Highlights:

• Thus streamlining the process for pharmacy appeals.
• It prohibits using a formulary to ban the use of certain pharmacies by an enrollee.
• It prohibits using formulary to ban the use of certain pharmacies by an enrollee.
• , and those contracts Those contracts are conducted between fairly sophisticated operators.
• Because the only end result of banning value-based contracting is higher drug prices.

Keywords: 965, house, all

Summary: The House Insurance Committee met on April 29 with a quorum present and considered several insurance- and health care-related bills. SB 192, concerning dental reimbursement and payment methods, was amended to clarify opt-in for electronic acceptance and then reported as amended. SB 84, which expands prostate cancer screening coverage for men over 40 and bars cost-sharing, was also amended and reported as amended after testimony from the American Cancer Society supporting earlier detection and reduced out-of-pocket barriers. SB 275, dealing with reimbursement and network access for certified registered nurse anesthetists, was reported favorably with broad support from nurse anesthetists, hospitals, and related groups. SB 169, a biomarker testing cleanup bill, was amended to clarify legislative intent and reported as amended. The committee spent substantial time on two major drug-pricing bills. SB 401 would create a Prescription Drug Affordability Board to study selected prescription drug prices, collect manufacturer and related pricing data, and report findings to the legislature; amendments narrowed the scope, addressed confidentiality, and delayed implementation. Supporters said it would provide transparency similar to Texas and help lawmakers understand drug pricing, while opponents warned about government overreach and confidentiality concerns. SB 387, the companion PBM reform bill, would restrict PBM compensation to flat fees and performance bonuses, require rebate pass-throughs, limit formulary practices, expand audit and reporting requirements, and create enforcement mechanisms; it was amended to delay implementation, refine definitions, and address ERISA-related concerns. Supporters argued it would curb PBM abuses and lower drug costs, while opponents from the Pelican Institute and PCMA said it would interfere with private contracts, reduce flexibility, and could raise premiums. After a roll call vote, SB 387 was reported with amendments. The committee also took up SB 241, which requires certain insurance adjusters and appraisers to include license numbers in written communications. After amendments narrowing the requirement to individual claims and public adjusters, the bill was reported as amended. Throughout the meeting, members repeatedly raised concerns about unintended consequences, especially for cities, school boards, and other non-ERISA plans, and sponsors said they would continue working on the drug-pricing bills before floor consideration.

Transcript Highlights:

• <00:57:48.960> pharmacy costs that are not a contract pharmacy costs that are not a contract
• , more than one contract pharmacy.
• more than one contract pharmacy. more than one contract pharmacy.
• have one contract pharmacy per clinic.
• <01:36:51.840> pharmacy House File 369 expands contract pharmacy House File 369 expands contract

Keywords: 919, house, all

Summary: The committee first approved the March 11, 2026 minutes, then heard House File 4048, which would exempt chiropractors from Minnesota’s provider tax if they are no longer eligible to provide chiropractic benefits under Medicaid/MinnesotaCare. Representative Robbins said the bill corrects an unfair situation because chiropractors still pay the tax even though the benefit was eliminated. Testifiers from the Minnesota Chiropractic Association and a longtime chiropractor supported the bill, arguing that most chiropractors are small-business owners and should not pay a tax for services they can no longer provide. Several members said they supported restoring chiropractic coverage instead of changing the tax, and there was discussion about whether the tax applies to all providers and whether it is effectively passed on to patients. The committee adopted a motion to recommend HF 4048 to the Committee on Taxes. The committee then took up House File 3893, as amended, a bill to restrict artificial intelligence from engaging in psychotherapy or counseling with humans. The author and supporters said the bill is intended to prevent AI chatbots from posing as therapists or counseling vulnerable people, citing reports of suicides and other harms linked to chatbot interactions. The A2 amendment was adopted; the author said it reflected stakeholder concerns and added informed-consent language. Testifiers in support, including a psychologist and a suicide-prevention nonprofit leader, urged strong safeguards and said AI should not replace licensed professionals in crisis settings. Other testimony raised concerns about overbreadth and unintended effects. TechNet and a rural mental health provider said the bill should be narrowed so it applies to clinical therapy rather than wellness or educational tools, and should allow supervised AI uses such as transcription and administrative support. Members discussed rural access, existing licensing-board authority, privacy laws, and whether the bill should target AI companies directly rather than licensed clinicians. The transcript ends during continued discussion of HF 3893, with no final committee action shown in the excerpt.

Transcript Highlights:

• So we analyze prescription drug spending under the pharmacy benefit, and pharmacy benefits are typically
• So we analyze prescription drug spending under the pharmacy benefit, and pharmacy benefits are typically
• called Pharmacy administered by entities called Pharmacy benefit<00:30:46.480> managers<00:30
• Pharmacy benefit manager Contracting<00:37:09.720> and<00:37:09.920> transparency Contracting
• <00:48:25.559> discount your data the V first pharmacy discount your data the V first pharmacy

Keywords: 928, house, all

Summary: The working session focused on the New Hampshire Prescription Drug Affordability Board’s budget request and its recent work. Early discussion centered on a technical question about a statutory dedicated fund for donations: members asked why the budget did not show a line item for accepting donations, and DHHS CFO Nathan White explained that the statute already authorizes the fund, but because no revenue has been received yet, it does not appear in the budget. He said any future donations would go through the normal process under RSA 14:30-a, with fiscal committee and Governor and Council approval and a memo to the Department of Revenue Administration. The chair clarified that the account was not a prerequisite to soliciting donations, and White said the fund would supplement, not replace, General Fund support. Kirk Williamson, the board’s executive director, then presented the board’s mission and budget. He said the governor’s budget provides about $256,500 in the first year and slightly more in the second, all General Funds, and that the board had distributed a technical amendment to continue the executive director position. He described the board’s role as analyzing prescription drug costs, identifying savings opportunities, monitoring market trends, promoting transparency, and making recommendations to the legislature and public payers. He also emphasized that the board operates publicly, with live-streamed meetings and a stakeholder advisory council that includes unions, state agencies, Medicaid, corrections, higher education, and other stakeholders. A major topic was the board’s estimate of $6 million in potential savings, based on Medicare’s newly negotiated prices for 10 drugs. Williamson explained that the board used those federal negotiated prices as a benchmark to estimate what New Hampshire public payers might be missing by not having similar leverage, and said the board is trying to build evidence for future recommendations rather than directly setting prices. Members asked how those potential savings could become actual savings, and Williamson said the board is sharing findings through its advisory council and feedback loops, though it has not yet sent a formal recommendation letter to specific purchasers. He also discussed the difference between pharmacy-benefit spending, which relies heavily on PBM-negotiated rebates, and medical-benefit spending, which is administered differently and is being added to the board’s next report. Williamson highlighted other work, including a model on Humira and a pending legislative effort to improve biosimilar competition, plus a proposed state-backed pharmacy savings card that would be no cost to the state and could save users about $240 per prescription based on Connecticut’s experience. No votes were taken during the session.

Transcript Highlights:

• This far as contracting has created a hardship on our community pharmacies, forcing them to financially
• to a community pharmacy.
• This forced contracting has created a hardship on our community pharmacies, forcing them to financially
• do to a community pharmacy.
• Their own pharmacies than they do to a community pharmacy.

Bills: SB65, SB248, SB330, SB378, SB844, SB1330, SB1410, SB1475, SB1476, SB1565, SB1618, SB1623, SJR39, SJR47, SB2084, SB1655, SB1679, SB2174, SB1775, SB1873, SB1204, SB1884, SB1916, SB1937, SB1447, SB1500, SB2007, SB2074, SB1944, SB2018, SB1984, SB2026, SB2045, SB2049, SB2062, SB2112, SB2118, SB2127, SB2134, SB2135, SB2139, SB2154, SB1195

Keywords: SB65, naloxone, Narcan, opioid overdose, overdose reversal, opioid antagonist, emergency opioid antagonist, substance abuse services, harm reduction, public health, overdose prevention, good samaritan, civil immunity, criminal immunity, controlled substances, addiction treatment, fentanyl, opioid crisis, school overdose response, first aid

Transcript Highlights:

• regulatory environment of pharmacy while fully preserving public protection.
• It does go well beyond traditional pharmacy practice.
• First, it confuses local pharmacies with manufacturers.
• licensees, which are pharmacies and pharmacists.
• Our industry is not stabilizing; it is contracting.

Keywords: 987, senate, all

Transcript Highlights:

• We can track pharmacies, but the pharmacies are not the ones filling the prescriptions; the pharmacists
• : it controls pharmacies, but you have pharmacies within assisted living facilities or nursing facilities
• : it controls pharmacies, but you have pharmacies within assisted living facilities or nursing facilities
• controls pharmacies, but you have pharmacies within assisted living facilities or nursing facilities
• We have contracted with Walker and Armstrong...

Keywords: 1182, all

Summary: The committee conducted sunset reviews for the Arizona State Board of Pharmacy, the State Board of Nursing, the Arizona Board of Occupational Therapy Examiners, and the Arizona Regulatory Board of Physician Assistants. The Auditor General’s reports praised each board for timely licensing in some areas but identified recurring problems with complaint investigations, public safety oversight, fee analysis, records/documentation, and internal controls. For Pharmacy, the main concerns were weak enforcement of controlled substances prescription monitoring program (CSPMP) requirements and slow complaint resolution; the board said it had implemented some recommendations, was pursuing a new database vendor, and supported legislation to strengthen CSPMP enforcement. For Nursing, the audit found a large and growing backlog of complaints and repeated delays in resolving cases; the executive director said the board was under-resourced and requested 28 additional investigative positions, while nursing stakeholders supported process reforms and cited a bill to improve timelines and fairness. For Occupational Therapy, the audit focused on missing or poorly documented fingerprint clearance card checks, delayed action on a serious criminal-charge disclosure, and other compliance issues; the board said it had accepted and was implementing all recommendations, including new procedures and rulemaking. For Physician Assistants, the audit found weak oversight by the executive director, extensive delays in complaint handling, and an incentive-pay system that did not align with key performance goals; the board said it had already made structural changes, was improving tracking and IT systems, and planned to continue implementing recommendations. After discussion and testimony from board officials, public members, and nursing stakeholders, the committee voted to continue the Arizona State Board of Pharmacy for six years until July 1, 2032, the State Board of Nursing for four years until July 1, 2031, the Arizona Board of Occupational Therapy Examiners for four years until July 1, 2030, and the Arizona Regulatory Board of Physician Assistants for a continued term with statutory changes (the transcript includes the board review and related discussion, but the final motion text for the physician assistants board is not fully captured in the excerpt). The votes on the first three continuations were approved by roll call, with members generally supporting continuation while expressing concern about complaint backlogs and the need for reforms.

Transcript Highlights:

• 00:31:30.840> contract."
• honor the terms of your contract, honor the terms of your contract, consumer,<00:32:07.440> average
• contract. That makes literally no sense. contract. That makes literally no sense.
• I'm the pharmacy director at DHS.
• We don't work for pharmacy plans.

Keywords: 1183, house

Transcript Highlights:

• THE BILL ADDRESSES PHARMACY BENEFIT MANAGER CONTRACTING PRACTICES BUILDING UPON THE LEGISLATION PASSED
• , WHETHER IT'S A SMALL PHARMACY OR BIG PHARMACY THAN WHAT THEY ARE ALLOWED TO SELL IT FOR, IS THE GAME
• ALL THE CONTRACTS WITH MANUFACTURERS ARE SECRET.
• THEIR OWN PHARMACIES, AGAIN AN INDICTMENT OF THE STATUS QUO, REIMBURSES THEIR OWN PHARMACIES, AGAIN
• LAST YEAR 1600 PHARMACIES WENT OUT OF BUSINESS, NOT ALL OF THEM WERE INDEPENDENT BUT IN DECEMBER 2 PHARMACIES

Transcript Highlights:

• underlying contract, is that correct?
• contract is that correct?
• So if the written contract has the one point of...
• When does that contract end? It will end in December of this year. So why do we need two contracts?
• When does that contract end? It will end in December of this year. So why do we need two contracts?

Summary: The State Insurance Programs Oversight Subcommittee met on June 17 and reviewed a series of Employee Benefits Division and Office of Property Risk items. The committee approved formulary changes for March and April that favored lower-cost generics, removed some new-to-market drugs from coverage pending more evidence, and made maintenance changes to migraine and diabetes medications. Members also approved a cell and gene therapy policy that would route those therapies through prior authorization rather than automatic coverage; officials said the process should not delay urgent cases and that no current members would be affected. The committee then reviewed a UAMS pharmacy benefit consultant contract amendment, but after extended discussion about the written scope and dollar amounts, the motion was approved with the understanding that any use of optional services would return to the committee for further review. The committee also reviewed the U.S. Able Mutual/Blue Advantage third-party administration contract and the CompSack employee assistance program contract, which officials said would reduce per-member costs and add services. The subcommittee approved proposed 2027 rates for state employees and public employees, with a 9.8% increase for state employees and a 4.9% increase for public school employees. Officials also reported that the UnitedHealthcare rebid was in its final negotiation stage and would return in August, with medical and pharmacy coverage split as previously recommended. In response to questions, the director said the division was considering broader preventive-care offerings, including weight-loss drug coverage, but would proceed cautiously and with strong utilization controls and holistic support if such a program were adopted. On the property risk side, the committee reviewed permanent rules making prior temporary rules permanent, a contingency-fee subrogation contract, and renewals for claims management, actuarial services, and investment management. Members raised concerns about Sedgwick’s claim-adjustment timeliness and communication with school districts after severe weather events; officials said performance guarantees and communication expectations had been strengthened, but the renewal was kept at three years for continuity. Finally, the committee approved 2026-27 captive insurance program rates, which included no change to minimum deductibles, a 10% overall rate reduction, and bucketed rate changes by entity type. Officials said the captive program was working as intended, with improved actuarial support and claims experience, and the meeting adjourned after the approvals.

Transcript Highlights:

• This particular bill is designed to prevent restrictions on the number of contract pharmacies.
• Various different pharmaceutical companies that either limit the number of contract pharmacies.
• Centered and not contract pharmacy or one of these other providers.
• The doctor prescribes it, goes to it now, or after this, a contract pharmacy, but it's been...
• But in fact, seven states have passed this kind of language that bans contract pharmacy restrictions,

Transcript Highlights:

• You had small rural pharmacies, and you had big, giant pharmacies.
• The rural pharmacies and the small pharmacies didn't want to have to accept that lower price, and so
• retail pharmacies.
• medical and pharmacy.
• Direct contracting? Right.

Keywords: 1184, house, all